Screener
Kyverna Therapeutics, Inc. KYTX Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity | ||
| Preferred stock, 10,000,000 shares authorized, $0.00001 par value, no shares issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.00001 par value; 490,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 60,532,500 and 60,389,893 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. | 1 | 1 |
| Additional paid-in capital | 660,230 | 657,005 |
| Accumulated other comprehensive income/(loss) | (96) | 97 |
| Accumulated deficit | (464,555) | (424,827) |
| Total stockholders’ equity | 195,580 | 232,276 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s common stock?
- Kyverna Therapeutics, Inc. (KYTX) reported common stock of $1K in Q1 2026.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Kyverna Therapeutics, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude